APA citiranje

Jimenez, C., Chin, B. B., Noto, R. B., Dillon, J. S., Solnes, L. B., DiPippo, V. A., . . . Pryma, D. A. (2020). OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety. J Endocr Soc.

Citação norma Chicago

Jimenez, Camilo, Bennett B. Chin, Richard B. Noto, Joseph Stephen Dillon, Lilja B. Solnes, Vincent A. DiPippo, Nancy Stambler, Vivien Wong, and Daniel A. Pryma. "OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients With Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety." J Endocr Soc 2020.

MLA citiranje

Jimenez, Camilo, et al. "OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients With Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety." J Endocr Soc 2020.